In two patients with metastatic breast cancer harboring different germline PTEN mutations who were enrolled in clinical trials, treatment with the catalytic AKT inhibitor capivasertib led to durable complete tumor responses, suggesting that targeted AKT therapy could be an effective strategy in patients with cancer having germline PTEN mutations. This evidence concerns the gene AKT1 and cancer.